| Nome |
# |
|
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients, file e268c4ca-aad0-a6b7-e053-3a05fe0adea1
|
160
|
|
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis, file e268c4ca-252b-a6b7-e053-3a05fe0adea1
|
114
|
|
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort, file e268c4c8-59a2-a6b7-e053-3a05fe0adea1
|
104
|
|
Effects of antagomiRs on different lung diseases in human, cellular, and animal models, file e268c4ca-cf45-a6b7-e053-3a05fe0adea1
|
99
|
|
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients, file e268c4c6-1d08-a6b7-e053-3a05fe0adea1
|
96
|
|
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting, file e268c4cc-c1e1-a6b7-e053-3a05fe0adea1
|
60
|
|
In-111 octreotide SPECT/CT in the early diagnosis of pulmonary sarcoidosis: A case report, file e268c4ce-310f-a6b7-e053-3a05fe0adea1
|
60
|
|
Immunoregulatory Role of HLA-G in Allergic Diseases, file e268c4cd-0ded-a6b7-e053-3a05fe0adea1
|
58
|
|
Il-33/il-31 axis in immune-mediated and allergic diseases, file e268c4cc-c38f-a6b7-e053-3a05fe0adea1
|
50
|
|
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and participating in the development of anti-inflammatory functional behavior of phagocytic macrophages, file e268c4c9-16bf-a6b7-e053-3a05fe0adea1
|
18
|
|
Immune homeostasis requires several biologic factors including glucocorticoid hormones, file e268c4c6-fa7c-a6b7-e053-3a05fe0adea1
|
14
|
|
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients, file e268c4c6-f6e7-a6b7-e053-3a05fe0adea1
|
12
|
|
Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus, file e268c4cc-28fe-a6b7-e053-3a05fe0adea1
|
12
|
|
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity., file e268c4c6-bb55-a6b7-e053-3a05fe0adea1
|
11
|
|
Vaccine-preventable infections in Systemic Lupus Erythematosus, file e268c4c7-24ff-a6b7-e053-3a05fe0adea1
|
6
|
|
Emerging biologic drugs for the treatment of rheumatoid arthritis, file e268c4c5-e706-a6b7-e053-3a05fe0adea1
|
4
|
|
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis, file e268c4c6-b9c4-a6b7-e053-3a05fe0adea1
|
4
|
|
In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion?, file e268c4c6-f6e3-a6b7-e053-3a05fe0adea1
|
4
|
|
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis, file e268c4c8-5211-a6b7-e053-3a05fe0adea1
|
4
|
|
Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer, file e268c4c7-28c4-a6b7-e053-3a05fe0adea1
|
3
|
|
Genetic factors and systemic sclerosis, file e268c4c8-4822-a6b7-e053-3a05fe0adea1
|
3
|
|
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy, file e268c4c8-4e19-a6b7-e053-3a05fe0adea1
|
3
|
|
Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis, file e268c4c8-5f64-a6b7-e053-3a05fe0adea1
|
3
|
|
Update upon the infection risk in patients receiving TNF alpha inhibitors, file e268c4c9-dd40-a6b7-e053-3a05fe0adea1
|
3
|
|
Stem cells therapy in acute myocardial infarction: a new era?, file e268c4cd-5b15-a6b7-e053-3a05fe0adea1
|
3
|
|
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events., file e268c4c5-f362-a6b7-e053-3a05fe0adea1
|
2
|
|
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis, file e268c4c5-f3b2-a6b7-e053-3a05fe0adea1
|
2
|
|
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events, file e268c4c6-141b-a6b7-e053-3a05fe0adea1
|
2
|
|
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome, file e268c4c6-1516-a6b7-e053-3a05fe0adea1
|
2
|
|
Defective expression and function of the leukocyte associated ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients, file e268c4c6-b15f-a6b7-e053-3a05fe0adea1
|
2
|
|
Long-term treatment of rheumatoid arthritis with adalimumab, file e268c4c8-5027-a6b7-e053-3a05fe0adea1
|
2
|
|
Endothelial dysfunction in rheumatic autoimmune diseases., file e268c4c8-52d6-a6b7-e053-3a05fe0adea1
|
2
|
|
Functional impairment of systemic scleroderma patients with digital
ulcerations: results from the DUO Registry, file e268c4c8-5cb0-a6b7-e053-3a05fe0adea1
|
2
|
|
HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact, file e268c4c9-923f-a6b7-e053-3a05fe0adea1
|
2
|
|
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis, file e268c4c9-96a8-a6b7-e053-3a05fe0adea1
|
2
|
|
Immunogenicity of infliximab and adalimumab, file e268c4ca-47f7-a6b7-e053-3a05fe0adea1
|
2
|
|
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis, file e268c4cb-bc90-a6b7-e053-3a05fe0adea1
|
2
|
|
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference, file e268c4cb-c719-a6b7-e053-3a05fe0adea1
|
2
|
|
Diagnosis of an unusual case of idiopathic mediastinal fibrosis by 18F-FDG PET/CT, file e268c4cc-c1e5-a6b7-e053-3a05fe0adea1
|
2
|
|
HLA-G Expressing Immune Cells in Immune Mediated Diseases, file e268c4cc-f631-a6b7-e053-3a05fe0adea1
|
2
|
|
Sjögren’s syndrome: a systemic autoimmune disease, file e268c4cd-b904-a6b7-e053-3a05fe0adea1
|
2
|
|
Letter to the Editor Regarding Erythropoietin-Stimulating Agents Resistance in Haemodialysis-Treated Patients: Time for a Treatment Shift?, file 91fce626-6ae0-44fe-80f8-4122199686ba
|
1
|
|
DECAY OF HIV-1 2LTR DNA IN INFECTED INDIVIDUALS AFTER THREE TO EIGHT YEARS OF SUSTAINED CONTROL OF VIREMIA., file e268c4c5-ecd3-a6b7-e053-3a05fe0adea1
|
1
|
|
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study)., file e268c4c5-f9a3-a6b7-e053-3a05fe0adea1
|
1
|
|
The impaired NK cell cytolytic function in viraemic HIV-1 infection is associated with a reduced surface expression of Natural Cytotoxicity Receptors (NKp46, NKp30 and NKp44), file e268c4c6-0015-a6b7-e053-3a05fe0adea1
|
1
|
|
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution., file e268c4c6-0360-a6b7-e053-3a05fe0adea1
|
1
|
|
Current views on diagnostic approach and treatment of lymphedema, file e268c4c6-1415-a6b7-e053-3a05fe0adea1
|
1
|
|
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment, file e268c4c6-141a-a6b7-e053-3a05fe0adea1
|
1
|
|
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment, file e268c4c6-141d-a6b7-e053-3a05fe0adea1
|
1
|
|
Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-gamma production after sublingual immunotherapy in patients with allergic rhinitis, file e268c4c6-f645-a6b7-e053-3a05fe0adea1
|
1
|
|
Infection risk associated with anti-TNF-α agents: A review, file e268c4c8-465e-a6b7-e053-3a05fe0adea1
|
1
|
|
Evaluation of membrane-bound and soluble forms of human leucocyte antigen-G in systemic sclerosis, file e268c4c9-8ec0-a6b7-e053-3a05fe0adea1
|
1
|
|
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study, file e268c4ca-687e-a6b7-e053-3a05fe0adea1
|
1
|
|
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response., file e268c4ca-9f7b-a6b7-e053-3a05fe0adea1
|
1
|
|
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety?, file e268c4ca-aad3-a6b7-e053-3a05fe0adea1
|
1
|
|
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications, file e268c4ca-fd63-a6b7-e053-3a05fe0adea1
|
1
|
|
The antiphospholipid syndrome: from pathophysiology to treatment, file e268c4ca-fd8f-a6b7-e053-3a05fe0adea1
|
1
|
|
An Uncommon Presentation of Pancreatic Carcinoma, file e268c4cc-432a-a6b7-e053-3a05fe0adea1
|
1
|
|
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis, file e268c4ce-3413-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
958 |